Prognostic significance of BCL-2 and BCL-6 expression in MYC positive-associate DLBCL lymphoma
Purpose: To investigate the significance of BCL-2 and BCL-6 expression in MYC positive-associate DLBCL lymphoma. Method: IHC was performed to evaluate the expression of BCL-2, BCL-6, MYC. Result: BCL-2 played a more import role compared to MYC in DEL patients, and BCL-6 negative expression might be a poor prognostic factor for DEL patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2018 Category: Hematology Authors: Linyu Li, Xuhan Zhang, Tingting Zhang, Zheng Song, Ge Hu, Wei Li, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianming Liu, Lixia Feng, Yi Pan, Qiongli Zhai, Bin Meng, Xiubao Ren, Kai Fu, Ping Wang, Xianhuo Wang, Huilai Zhang Tags: Original Study Source Type: research

A Review of Small Molecules and Their Therapeutic Targets
Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation (ASCT), has changed dramatically in the past 20 years as three new classes of small molecule drugs (arbitrarily defined as having molecular weights of less than 900 kDa) - immunomodulators (IMiDs), proteasome inhibitors (PIs), and histone deacetylase (HDAC) blockers - have been introduced for the disease. Therapeutic options for MM expanded further in 2015 when two new monoclonal antibodies (daratumumab and elotuzumab) were approved by the FDA for MM. (Source: Cli...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2018 Category: Hematology Authors: Hanley N. Abramson Tags: Review Article Source Type: research

Venetoclax in combination with bortezomib, dexamethasone and daratumumab for multiple myeloma
Multiple myeloma (MM) is an incurable plasma cell dyscrasia with a five-year overall survival of 49.6% that is estimated to currently affect 118,539 people in the United States.1 Despite recent advances that have improved outcomes, MM patients inevitably become refractory to therapy; and, thus, must rely on a diversity of treatment options for long-term management of their disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2018 Category: Hematology Authors: Kian J. Rahbari, Jason D. Nosrati, Tanya M. Spektor, James R. Berenson Tags: Case Report Source Type: research

Hodgkin Lymphoma with Multiple Autoimmune Disorders: A Case Report and Review of the Literature
There is a known association between Hodgkin lymphoma (HL) and autoimmune disorders with several case reports and case series describing diseases such as immune thrombocytopenia (ITP) in patients with HL, as well as population studies depicting a link between these phenomena. The following case report describes a patient initially presenting with ITP and subsequently being diagnosed with HL as well as primary biliary cirrhosis (PBC) and Hashimoto ’s thyroiditis. This case is unique as it is one of only a few case reports describing multiple autoimmune conditions in one patient with HL and in this scenario, the thromb...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2018 Category: Hematology Authors: Natalie S. Grover, Christopher E. Dittus, Alice D. Ma, Steven I. Park Tags: Case Report Source Type: research

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma
Treatment outcomes have improved in lymphoid malignancies but relapse remains inevitable in most patients. Everolimus (RAD) and lenalidomide (LEN) have shown clinical activity as single agents in patients with relapsed and refractory (R/R) Hodgkin and non-Hodgkin lymphomas. This Phase I/II trial for patients with R/R lymphoid malignancy opened at Mayo Clinic between January 2011 and May 2013 utilized a standard cohort of 3+3 design to determine the Maximum Tolerated Dose(MTD) of the combination. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2018 Category: Hematology Authors: Leslie Padrnos, Brenda Ernst, Amylou C. Dueck, Heidi E. Kosiorek, Brenda F. Ginos, Angela Toro, Patrick B. Johnston, Thomas M. Habermann, Jose F. Leis, Joseph R. Mikhael, Grzegorz S. Nowakowski, Joseph Colgan, Luis Porrata, Stephen M. Ansell, Thomas E. Wi Tags: Original Study Source Type: research

Interim PET-CT result is not predictive of survival in patients with MYC-rearranged non-Burkitt aggressive B cell lymphoma
Patients diagnosed with MYC-rearranged non-Burkitt aggressive B cell lymphoma (MYC-R), including those with double hit lymphoma, are at high risk for developing relapsed/refractory disease, even if treated with intensive front-line immunochemotherapy. It is common in clinical practice as well as clinical trials to perform an interim PET-CT scan (iPET) during front-line therapy for diffuse large B cell lymphoma, however the utility of iPET result in MYC-R patients with regards to predicting outcomes is unclear. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2018 Category: Hematology Authors: Hua-Jay J. Cherng, Rachel Lynn Sargent, Sunita Dwivedy Nasta, Jakub Svoboda, Stephen J. Schuster, Anthony R. Mato, April Schrank-Hacker, Jennifer J.D. Morrissette, Daniel J. Landsburg Tags: Original Study Source Type: research

A Pilot Trial of Lirilumab with or without Azacitidine for patients with Myelodysplastic Syndrome
We report the results of a prospective trial of lirilumab in patients with myelodysplastic syndrome(MDS). A total of 10 patients included. Higher-risk patients received lirilumab plus azacitidine, lower-risk received single agent lirilumab. Two patients achieved CR and 5 achieved marrow CR. Although the small sample size precludes definitive conclusions, the results of this study indicate the efficacy and safety of lirilumab in MDS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2018 Category: Hematology Authors: Fevzi Firat Yalniz, Naval Daver, Katayoun Rezvani, Steven Kornblau, Maro Ohanian, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Jan Burger, Yvonne Gasior, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero Tags: Original Study Source Type: research

Prevalence of Monoclonal Gammopathy of Undetermined Significance in India- A Hospital Based Study
A cross sectional hospital based study was undertaken over a period of 3 months to ascertain the prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) in North India. Of the 3429 patients evaluated, MGUS was detected in 49 (1.43%) and multiple myeloma (MM) in six (0.17%). This is the first systematic study on the prevalence of MGUS in Indian population and highlights the relatively low incidence of MGUS in Indians as compared with Caucasians and African-Americans. The incidental detection of MM in this study points towards the need for creating awareness regarding myeloma related symptoms in appropriate a...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 12, 2018 Category: Hematology Authors: Ritu Gupta, Meetu Dahiya, Lalit Kumar, Varun Shekhar, Atul Sharma, Lakshmy Ramakrishnan, Om Dutt Sharma, Abida Begum Tags: Original Study Source Type: research

FLT3-TKD mutations associated to NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia
Outcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial. Herein we present a retrospective study of 126 newly diagnosed AML patients performed in two French centers. FLT3-TKD mutations represented 12.7% of patients, while FLT3-internal tandem duplication (ITD) mutation was observed in 20.6% of AML cases and 1.6% of patients harbored both anomalies. At diagnosis, FLT3-TKD and FLT3-ITD were associated with higher peripheral leukocytes count and a higher blast count in bone marrow (P (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 12, 2018 Category: Hematology Authors: Marielle Perry, Sarah Bertoli, Cl ément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne Paubelle Tags: Original Study Source Type: research

Identifying Tyrosine Kinase Inhibitor Non-adherence in Chronic Myeloid Leukemia: a sub-analysis of the TAKE-IT pilot study
Identifying non-adherence in chronic myeloid leukemia (CML) remains a challenge. Tyrosine kinase inhibitor adherence was measured by electronic monitoring and BAASIS © self-report in 55 CML patients over 4 months. The BAASIS© had 67% sensitivity and 71% specificity for diagnosing non-adherence. The BAASIS© and the risk factors for non-adherence found in this study provide a basis for identifying non-adherent CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 12, 2018 Category: Hematology Authors: Avi Leader, Anat Gafter – Gvili, Noam Benyamini, Juliet Dreyer, Bronya Calvarysky, Alina Amitai, Osnat Yarchovsky-Dolberg, Giora Sharf, Eric Tousset, Opher Caspi, Martin Ellis, Itai Levi, Pia Raanani, Sabina De Geest Tags: Original Study Source Type: research

Bone Health and Survival in Women with Multiple Myeloma
Multiple Myeloma is a disease of aging adults resulting in osteolytic and/or osteoporotic bone disease. Primary osteoporosis is also highly prevalent in aging adults and is associated with increased mortality. It is unknown how concurrent osteoporosis is associated with outcomes in patients who develop Multiple Myeloma (MM). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2018 Category: Hematology Authors: Ashley E. Rosko, Erinn M. Hade, Wenjun Li, Steven Ing, Rebecca D. Jackson, Electra D. Paskett, Michelle J. Naughton Tags: Original Study Source Type: research

Molecular markers and prognosis of myelofibrosis in the genomic era: a meta-analysis
Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline to October 31, 2017 was performed. More than three studies compared overall survival (OS) and leukemia-free survival (LFS) were eligible. A total of 16 studies were included. HR for OS were as follows: IDH 2.65 (95%CI 1.66-4.21), SRSF2 2.12 (1.18-3.79), HRM 2.11 (1.70-2.61), ASXL1 1.92 (1.60-2.32), EZH2 1.88 (1.32-2.67), JAK2 1.41 (1.04-1.93) in the univariate analysis and 1.49 (95% 0.42-5.30) in the multivariate analysis. (Source: Clinica...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2018 Category: Hematology Authors: Yen-Chien Lee, Chung-Cheng Hsieh, Yen-Ling Lee, Chung-Yi Li Tags: Review Article Source Type: research

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
In an open-label, phase II study, we evaluated entospletinib monotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma. Entospletinib had limited activity in these patients. Seventy-four percent of the patients experienced a grade  ≥ 3 adverse event. Treatment was interrupted in 42% of the patients, and the drug was discontinued in 19% of the patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 6, 2018 Category: Hematology Authors: John M. Burke, Andrei Shustov, James Essell, Dipti Patel-Donnelly, Jay Yang, Robert Chen, Wei Ye, Wen Shi, Sarit Assouline, Jeff Sharman Tags: Original Study Source Type: research

An open-label, phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma
An open-label, phase 2 study evaluated entospletinib monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Entospletinib had limited activity in these patients. Seventy-four percent of patients experienced a grade ≥ 3 adverse event. Treatment was interrupted in 42% of pat ients, and drug was discontinued in 19% of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 6, 2018 Category: Hematology Authors: John M. Burke, Andrei Shustov, James Essell, Dipti Patel-Donnelly, Jay Yang, Robert Chen, Wei Ye, Wen Shi, Sarit Assouline, Jeff Sharman Tags: Original Study Source Type: research

A Phase 2 Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Patients with relapsed/refractory non-Hodgkin lymphomas remain a population of unmet medical need. Histone deacetylase inhibitors (HDACIs) and proteasome inhibitors have shown synergistic interactions pre-clinically in several B-cell malignancies. This phase 2 trial examined the combination of the proteasome inhibitor bortezomib and the HDACI vorinostat in patients with relapsed/refractory diffuse large B-cell lymphoma or mantle cell lymphoma. The results of this trial reveal a modest overall response rate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 5, 2018 Category: Hematology Authors: Victor Yazbeck, Danielle Shafer, Edward B. Perkins, Domenico Coppola, Lubomir Sokol, Kristy L. Richards, Thomas Shea, Jia Ruan, Samir Parekh, Roger Strair, Christopher Flowers, David Morgan, Maciej Kmieciak, Prithviraj Bose, Amy Kimball, Ashraf Z. Badros, Tags: Original Study Source Type: research

Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma
Hodgkin lymphoma (HL) patients have excellent outcomes but second cancers (SCs) gain importance with survivorship. The Surveillance, Epidemiology, and End Results database was used to determine the risk of SCs. The overall risk of SCs in HL patients declined over time but the risk of SCs at several organ sites remained the same, necessitating the need for ongoing targeted surveillance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 29, 2018 Category: Hematology Authors: Vivek Kumar, Mohit Garg, Abhinav B. Chandra, Valerie S. Mayorga, Salman Ahmed, Sikander Ailawadhi Tags: Original Study Source Type: research

Trends In The Risks Of Secondary Cancers In Patients Of Hodgkin ’s Lymphoma
Hodgkin ’s lymphoma (HL) patients have excellent outcomes but second cancers (SC) gain importance with survivorship. The Surveillance, Epidemiology and End Results database was utilized. The overall risk of SCs in HL patients declined over time but risk of SCs at several organ sites remained the same, nec essitating the need for ongoing targeted surveillance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 29, 2018 Category: Hematology Authors: Vivek Kumar, Mohit Garg, Abhinav Chandra, Valerie S. Mayorga, Salman Ahmed, Sikander Ailawadhi Source Type: research

Hypomethylating Agents-associated Infections —Systematic Review and Meta-analysis of Randomized Controlled Trials
Data regarding the effects of hypomethylating agents on the risk of infections are lacking. Therefore, we conducted a systematic review and meta-analysis of all randomized controlled trials comparing hypomethylating agent-containing regimens with any other regimen for patients with myeloid neoplasms. Treatment with hypomethylating agents was associated with an increase in the grade 3/4 infection rate compared with the comparator. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 28, 2018 Category: Hematology Authors: Liat Shargian-Alon, Ronit Gurion, Pia Raanani, Dafna Yahav, Anat Gafter-Gvili Tags: Original Study Source Type: research

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
In patients with a complete response (CR), high-dose therapy with autologous stem cell transplantation (HDT-ASCT) consolidation improved progression-free survival (PFS), second PFS (PFS2), and overall survival (OS) versus R-Alk (lenalidomide, alkylator) consolidation. Also, lenalidomide maintenance therapy enhanced PFS compared with no maintenance therapy. The survival advantage with HDT-ASCT compared with R-Alk in CR patients can be attributed to the greater minimal residual disease negativity rate induced by HDT-ASCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 28, 2018 Category: Hematology Authors: Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, Stefano Spada, Francesca Patriarca, Chiara Cerrato, Lorenzo De Paoli, Norbert Pescosta, Roberto Ria, Alessandra Malfitano, Pellegrino Musto, Luca Baldini, Tommasina Guglielmelli, Barbara Gamberi, Donat Tags: Original Study Source Type: research

Aseptic meningitis as a complication of daratumumab therapy
The treatment of relapsed multiple myeloma has been greatly improved by the use of targeted antibody therapy. Daratumumab is a humanized IgG monoclonal antibody that targets CD38, a transmembrane protein expressed on many cell types including myeloma cells, hematopoietic progenitor cells, and endothelial cells.1 It shows single-agent activity in highly advanced myeloma, leading to FDA approval.2 It was also approved in combination with standard myeloma drugs such as lenalidomide, pomalidomide, and bortezomib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 28, 2018 Category: Hematology Authors: Kimaya Reddy, Myo Htut, Amrita Krishnan, Sanjeet Dadwal Tags: Case Report Source Type: research

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
Data from REVEAL (the first prospective, observational, noninterventional study of US patients with polycythemia vera; N=2309) confirm that many patients experience quality-of-life and work productivity impairments that may negatively impact their lives. In the future, longitudinal data from REVEAL will be important for evaluating how such burdens change over time. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 28, 2018 Category: Hematology Authors: Ruben Mesa, Ralph V. Boccia, Michael R. Grunwald, Stephen T. Oh, Philomena Colucci, Dilan Paranagama, Shreekant Parasuraman, Brady L. Stein Source Type: research

Treatment intensification with autologous stem-cell transplantation and lenalidomide maintenance improves survival outcomes of newly diagnosed multiple myeloma patients in complete response
In CR patients, HDT-ASCT consolidation improved PFS, PFS2 and OS vs R-Alk consolidation, and R- maintenance also enhanced PFS vs no maintenance. The survival advantage with HDT-ASCT over R-Alk in CR patients may be attributed to a higher MRD negativity rate induced by HDT-ASCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 28, 2018 Category: Hematology Authors: Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, Stefano Spada, Francesca Patriarca, Chiara Cerrato, Lorenzo De Paoli, Norbert Pescosta, Roberto Ria, Alessandra Malfitano, Pellegrino Musto, Luca Baldini, Tommasina Guglielmelli, Barbara Gamberi, Donat Tags: Original Study Source Type: research

Hypomethylating agents associated infections - systematic review and meta-analysis of randomized controlled trials
Data regarding the effects of hypomethylating agents on the risk of infections are lacking. Therefore, we conducted a systematic review and meta ‐analysis of all randomized controlled trials comparing hypomethylating agents containing regimens to any other regimen in patients with myeloid neoplasms. Treatment with hypomethylating agents was associated with an increase in grade 3-4 infection rate compared to the comparator. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 28, 2018 Category: Hematology Authors: Liat Shargian-Alon, Ronit Gurion, Pia Raanani, Dafna Yahav, Anat Gafter-Gvili Tags: Original Study Source Type: research

Acute liver failure associated with pomalidomide therapy for multiple myeloma
Pomalidomide is a thalidomide-derived immunomodulatory drug (IMiD) that is used in the treatment of refractory multiple myeloma. Pomalidomide ’s major toxicity is neutropenia, and non-hematologic toxicities are uncommon. Severe hepatotoxicity was not observed in the major clinical trials of pomalidomide1–6 for multiple myeloma. Risk of fatal hepatotoxicity was added to the drug’s US prescribing information in 2015, though few cases of severe hepatotoxicity have been described in the published literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 26, 2018 Category: Hematology Authors: Lauren Reed-Guy, Maarouf A. Hoteit, Alfred L. Garfall Tags: Case Report Source Type: research

Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients
In a large study focusing on the impact of CD135 on clincal presentation and its relation to other prognostic parameters, we addressed whether CD135 could be predictor of FMS-like tyrosine kinase 3 (FLT3) mutation. We found an association between CD135 expression and persistence of positive minimal residual disease postinduction status. CD135 is a crucial indicator of unfavorable outcome that influences complete remission status, disease-free survival, and overall survival in adult Egyptian acute myeloid leukeia patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 25, 2018 Category: Hematology Authors: Eman Z. Kandeel, Ghada El Sayed, Nahla Elsharkawy, Dalia Negm Eldin, Hanan R. Nassar, Dalia Ibrahiem, Randa Amin, Marwa Hanafi, Mohamed Khalil, Azza Kamel Tags: Original Study Source Type: research

Clinical Outcomes with Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndrome: MDS Clinical Research Consortium Analysis
We report outcomes of MDS patients with SF3B1 mutation in presence or absence of RS and their response to current available therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 25, 2018 Category: Hematology Authors: Yazan Migdady, John Barnard, Najla Al Ali, David P. Steensma, Amy DeZern, Gail Roboz, Guillermo Garcia-Manero, Mikkael A. Sekeres, Rami S. Komrokji Tags: Original Study Source Type: research

Impact of FLT3 receptor (CD135) detection by flow cytomtery on clinical outcome of adult acute myeloid leukemia patients
Significance of FLT3-ITD mutation in AML prognosis has been well established. The aim of this study was to investigate the prognostic impact of the FLT3 protein (CD135) expression, its association with FLT3-ITD mutation and to identify its role in minimal residual disease (MRD). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 25, 2018 Category: Hematology Authors: Eman Z. Kandeel, Ghada El Sayed, Nahla Elsharkawy, Dalia Negm Aldin, Hanan R. Nassar, Dalia Ibrahiem, Randa Amin, Marwa Hanafi, Mohamed Khalil, Azza Kamel Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Source Type: research

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes
In the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome (MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second, quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS. The research devoted to clarifying the mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced, mostly resulting from different approaches to the study of DNA ...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Valeria Santini Tags: Review Source Type: research

SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
The widespread adoption of Bcr –Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of  (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Nicholas J. Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias Jabbour Tags: Review Source Type: research

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma
Combination regimens with anti-CD20 agents may improve outcomes of patients with relapsed or refractory B-cell malignancies, but comparative clinical evidence is limited. This review assessed the published evidence on the efficacy of anti-CD20 monoclonal antibodies in combination with chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment (REA) approach. MEDLINE ®, Embase® and the Cochrane Library were searched from January 1, 1997 to July 14, 2017 (English language only). (Source:...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, Pilar Nava-Parada Tags: Review Article Source Type: research

Feasibility and efficacy of high-dose chemotherapy and autologous hematopoietic cell transplantation for HIV-associated lymphoma: a single-institution experience
HIV- associated lymphomas (HAL) remain an important cause of morbidity and mortality in HIV patients, especially in the refractory setting. Hematopoietic cell transplantation (HCT) is considered a curative option for patients with refractory HAL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Ernesto Ayala, Julio C. Chavez, Alexandra Gomez, Elsa Sleiman, Ambuj Kumar, Mohamed A. Kharfan-Dabaja Tags: Original Study Source Type: research

Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms
Chronic myelomonocytic leukemia (CMML) is a relatively uncommon hematologic malignancy that manifests as peripheral monocytosis, varying degrees of bone marrow dysplasia, and is associated with poor outcomes. Despite growing appreciation of the pathobiological mechanisms driving CMML, current therapies have not clearly demonstrated survival benefit. The complex pathobiology of CMML highlights the intricate aberrantly activated cellular pathways that influence disease phenotype and limit current treatment options. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Anita Geevarghese, John Mascarenhas Tags: Review Article Source Type: research

SOHO State of the Art Update & Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
The widespread adoption of Bcr-Abl-directed tyrosine kinase inhibitors (TKIs) into frontline regimens for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of less than 25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (e.g. ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual diseas...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Nicholas J. Short, Hagop Kantarjian, Ching Hon Pui, Anthony Goldstone, Elias Jabbour Tags: Review Article Source Type: research

“Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions”: MDS
In the last few months two main streams of research have dominated the panorama of myelodysplastic syndrome investigations: one deepening the insight into pathogenic role, hierarchy and prognostic impact of somatic mutations and, as a consequence, into the impact of inherited congenital predisposing conditions; the second, quite interlinked in fact to the first one, analysing inflammation and innate immunity in myelodysplastic syndrome patients. The research devoted to clarifying mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced, mostly because of different approaches to the stud...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2018 Category: Hematology Authors: Valeria Santini Tags: Review Article Source Type: research

Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients
On the basis of the study of 205 Chinese patients with multiple myeloma, we demonstrated a prevalence of 9.3% of BRAF V600E mutation, the highest hitherto reported. Additionally, BRAF V600E mutation was found to be associated with hypercalcemia and a male predominance. In subgroup analysis, the BRAF V600E mutation showed prognostic impact on overall survival in younger patients ( (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 14, 2018 Category: Hematology Authors: Coty H.Y. Cheung, Chi Keung Cheng, Kin-Mang Lau, Rosalina K.L. Ip, Nelson C.N. Chan, Tommy H.C. Tam, Raymond S.M. Wong, Radha Raghupathy, Natalie P.H. Chan, Margaret H.L. Ng Tags: Original Study Source Type: research

Prevalence and clinicopathological significances of BRAF V600E mutation in Chinese multiple myeloma patients
Based on the study of 205 Chinese patients with multiple myeloma, we demonstrated a prevalence of 9.3% of BRAF V600E mutation, the highest hitherto reported. Additionally, BRAF V600E mutation was found to be associated with hypercalcemia and a male predominance. In subgroup analysis, the BRAF V600E mutation showed prognostic impact on overall survival in younger patients less than 65 years of age. This is the first large scale study revealing the prevalence and clinicopathological significances of BRAF V600E mutation in Chinese myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 14, 2018 Category: Hematology Authors: Coty H.Y. Cheung, Chi Keung Cheng, Kin-Mang Lau, Rosalina K.L. Ip, Nelson C.N. Chan, Tommy H.C. Tam, Raymond S.M. Wong, Radha Raghupathy, Natalie P.H. Chan, Margaret H.L. Ng Tags: Original Study Source Type: research

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat
Recent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges because of the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to optimally use new therapeutic agents. Panobinostat is the first histone deacetylase inhibitor approved for the treatment of multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2018 Category: Hematology Authors: Jamie D. Cavenagh, Rakesh Popat Tags: Review Source Type: research

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics, and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 (3 days of anthracycline and 7 days of cytarabine) induction and absence of monosomal karyotype to positively predict complete remission whereas positive predictors of overall survival were younger age and the absence of monosomal karyotype. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2018 Category: Hematology Authors: Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola, Ishmael Jaiyesimi Tags: Original Study Source Type: research

Predictive and Prognostic Markers in Adults with Acute Myeloid Leukemia; a Single Institution Experience
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 induction and absence of monosomal karyotype to positively predict complete remission while positive predictors of overall survival were younger age and the absence of monosomal karyotype. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2018 Category: Hematology Authors: Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola, Ishmael Jaiyesimi Tags: Original Study Source Type: research

Optimal Management of Histone Deacetylase Inhibitor –Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat
Recent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges given the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to use new therapeutic agents optimally. Panobinostat is the first histone deacetylase inhibitor approved for the treatment of multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2018 Category: Hematology Authors: Jamie D. Cavenagh, Rakesh Popat Tags: Review Article Source Type: research

Investigational Antibody –Drug Conjugates for Treatment of B-lineage Malignancies
Antibody –drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen–antibody interactions to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity and simultaneously minimize off-target toxicity. The earliest ADCs provided disappointing results in the clinic; however, the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and greater potency payloads led to improved ADCs. (Source: Clinical Lymphoma...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Alex F. Herrera, Arturo Molina Tags: Review Source Type: research

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients from the Polish Adult Leukemia Group (PALG) Registry
To the Editor, (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Joanna Gora-Tybor, Tomasz Sacha, Joanna W ącław, Joanna Niesiobędzka-Krężel, Olga Grzybowska-Izydorczyk, Ewa Mędraś, Izabela Dereń-Wagemann, Elżbieta Patkowska, Ilona Seferyńska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Tags: Letter to the Editor Source Type: research

Investigational Antibody-Drug Conjugates (ADCs) for the Treatment of B-Lineage Malignancies
Antibody-drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen-antibody interactions in order to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity while simultaneously minimizing off-target toxicity. The earliest ADCs provided disappointing results in the clinic, but the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and higher potency payloads led to improved ADCs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Alex F. Herrera, Arturo Molina Tags: Review Article Source Type: research

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients with Acute Myeloid Leukemia: A Systematic Literature Review
Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one-third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly ( ≥60 years old) patients with AML.Published literature on the topic was scant, and the review included only 22 articles examining outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller Tags: Review Article Source Type: research

Evaluation of parameters related to the probability of leukemic progression in patients with lower-risk myelodysplastic syndrome
Several prognostic factors such as intermediate karyotype, presence of 5-9% bone marrow blasts and platelet count (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Jose F. Falantes, Francisco J. M árquez-Malaver, Cristina Calderón-Cabrera, Begoña Pedrote, María L. Martino, Jose González, Ildefonso Espigado, Jose A. Pérez-Simón Tags: Original Study Source Type: research

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational  Study
In the present study, we identified 37 patients with chronic myeloid leukemia in 7 medical centers to study how ponatinib is used outside of clinical trials. At least 1 previous tyrosine kinase inhibitor had failed in all 37 patients. Their median age was 43 years (range, 9-82 years), and the overall response rate was 85%. Outside of clinical trials, ponatinib has been reserved for exceptionally young patients; however, responses can be expected even in heavily pretreated patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 7, 2018 Category: Hematology Authors: Adi Shacham-Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Helman, Liat Shargian, Anna Gourevitch, Evgeni Chubar, Roy Ratzon, Uri Rozovski Tags: Original Study Source Type: research

Real-life experience with ponatinib in chronic myeloid leukemia (CML): A multicenter observational study
To study how ponatinib is used outside clinical trials, we identified 37 patients with CML in 7 medical centers; all failed at least one prior TKI. The median age was 43 years (range: 9 - 82) and the overall response rate was 85%. Hence, in real-life, ponatinib is reserved for exceptionally young patients. Responses are expected even in heavily pretreated patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 7, 2018 Category: Hematology Authors: Adi Shacham-Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Helman, Liat Shargian, Anna Gourevitch, Evgeni Chubar, Roy Ratzon, Uri Rozovski Tags: Original Study Source Type: research

Surrogate Endpoints and Risk Adaptive Strategies In Previously Untreated Follicular Lymphoma
Follicular lymphoma is the second most common subtype of non-Hodgkin ’s lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in th e front-line setting. Long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus, clinical trials require approximately 5 to 8 years from activation to completion and analysis of outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2018 Category: Hematology Authors: M.S. Narkhede, B.D. Cheson Tags: Review Article Source Type: research